Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

BACKGROUND: Metastatic urothelial carcinoma (mUC) is a genomically diverse disease with known alterations in the mTOR pathway and tyrosine kinases including FGFR. We investigated the efficacy and safety of combination treatment with everolimus and pazopanib (E/P) in genomically profiled patients wit...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: Bellmunt, Joaquim, Lalani, Aly-Khan A., Jacobus, Sussana, Wankowicz, Stephanie A., Polacek, Laura, Takeda, David Y., Harshman, Lauren C., Wagle, Nikhil, Moreno, Irene, Lundgren, Kevin, Bossé, Dominick, Van Allen, Eliezer M., Choueiri, Toni K., Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173710/
https://ncbi.nlm.nih.gov/pubmed/30220708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0261-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares